SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,646,452 | -10.2% | 531,246 | -2.1% | 0.00% | -20.0% |
| Q2 2023 | $16,307,791 | -11.7% | 542,508 | +6.4% | 0.01% | -16.7% |
| Q1 2023 | $18,470,271 | +2.0% | 509,806 | +0.5% | 0.01% | 0.0% |
| Q4 2022 | $18,100,777 | +14.3% | 507,451 | +8.5% | 0.01% | 0.0% |
| Q3 2022 | $15,834,000 | +27.5% | 467,774 | +8.9% | 0.01% | +50.0% |
| Q2 2022 | $12,420,000 | -4.5% | 429,451 | +6.8% | 0.00% | 0.0% |
| Q1 2022 | $13,003,000 | +20.8% | 402,290 | +9.0% | 0.00% | +33.3% |
| Q4 2021 | $10,763,000 | +11.5% | 369,092 | +2.0% | 0.00% | 0.0% |
| Q3 2021 | $9,655,000 | -25.1% | 362,005 | -13.5% | 0.00% | -25.0% |
| Q2 2021 | $12,887,000 | +9.2% | 418,540 | -7.2% | 0.00% | 0.0% |
| Q1 2021 | $11,806,000 | +6.8% | 450,929 | +2.6% | 0.00% | 0.0% |
| Q4 2020 | $11,058,000 | +18.8% | 439,497 | -1.6% | 0.00% | 0.0% |
| Q3 2020 | $9,310,000 | +14.2% | 446,714 | +30.2% | 0.00% | 0.0% |
| Q2 2020 | $8,149,000 | +41.5% | 343,082 | +7.2% | 0.00% | +33.3% |
| Q1 2020 | $5,760,000 | -40.1% | 320,144 | -21.0% | 0.00% | -40.0% |
| Q4 2019 | $9,616,000 | -12.3% | 405,368 | +1.6% | 0.01% | -16.7% |
| Q3 2019 | $10,966,000 | -7.1% | 399,048 | +11.9% | 0.01% | -14.3% |
| Q2 2019 | $11,804,000 | +2.1% | 356,724 | +8.1% | 0.01% | 0.0% |
| Q1 2019 | $11,565,000 | +9.6% | 330,037 | +3.9% | 0.01% | -12.5% |
| Q4 2018 | $10,554,000 | -32.7% | 317,688 | +2.0% | 0.01% | -20.0% |
| Q3 2018 | $15,690,000 | -9.0% | 311,599 | +8.2% | 0.01% | -23.1% |
| Q2 2018 | $17,234,000 | +18.9% | 287,937 | -9.0% | 0.01% | +18.2% |
| Q1 2018 | $14,494,000 | +27.2% | 316,446 | +10.6% | 0.01% | +22.2% |
| Q4 2017 | $11,398,000 | +20.1% | 286,003 | +20.5% | 0.01% | +12.5% |
| Q3 2017 | $9,491,000 | +8.4% | 237,271 | +16.8% | 0.01% | 0.0% |
| Q2 2017 | $8,758,000 | +43.3% | 203,197 | +4.1% | 0.01% | +33.3% |
| Q1 2017 | $6,113,000 | +31.1% | 195,279 | +5.7% | 0.01% | +20.0% |
| Q4 2016 | $4,664,000 | -1.4% | 184,707 | -3.5% | 0.01% | -16.7% |
| Q3 2016 | $4,732,000 | +69.5% | 191,317 | +39.6% | 0.01% | +100.0% |
| Q2 2016 | $2,792,000 | +42.3% | 137,023 | +6.5% | 0.00% | 0.0% |
| Q1 2016 | $1,962,000 | -53.4% | 128,636 | -58.9% | 0.00% | -50.0% |
| Q4 2015 | $4,208,000 | -15.5% | 313,091 | -11.8% | 0.01% | -14.3% |
| Q3 2015 | $4,978,000 | +94.4% | 354,785 | +135.3% | 0.01% | +75.0% |
| Q2 2015 | $2,561,000 | +103.3% | 150,786 | +44.7% | 0.00% | +100.0% |
| Q1 2015 | $1,260,000 | +130.8% | 104,208 | +58.7% | 0.00% | +100.0% |
| Q4 2014 | $546,000 | +46.0% | 65,669 | +52.7% | 0.00% | 0.0% |
| Q3 2014 | $374,000 | -20.6% | 43,000 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $471,000 | +65.3% | 43,000 | +35.2% | 0.00% | 0.0% |
| Q1 2014 | $285,000 | +18.8% | 31,800 | 0.0% | 0.00% | – |
| Q4 2013 | $240,000 | +2.6% | 31,800 | 0.0% | 0.00% | – |
| Q3 2013 | $234,000 | -8.2% | 31,800 | -19.9% | 0.00% | -100.0% |
| Q2 2013 | $255,000 | – | 39,709 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |